Open House Originale rebate agreements for Dapagliflozin
Titre original de l'avis
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-07 - Dapagliflozin
Score d'opportunité
Pourquoi ce score ?
Opportunité
56 / 100
Complexité
48 / 100
Facteurs de risque
Contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature or by...
Only pharmaceutical entrepreneurs meeting the AMG and authorisation conditions may participate.
Submission deadline in 3 days
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Supplies contract
- 1 lot
- Duration until Aug 2026
- Conclusion of rebate agreements for the medicinal product Dapagliflozin under Section 130c SGB V.
- Uniform Open House terms apply; no individual negotiation of contract content.
Afficher le résumé complet
Open House supply arrangement for Dapagliflozin pharmaceutical products in Germany, led by Techniker Krankenkasse with participating sickness funds. It is not a classic public procurement award procedure; contracts are concluded on uniform terms with all eligible pharmaceutical companies that meet the stated conditions. No contract value is stated. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and documents are only provided electronically to eligible companies.
Risques
Contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature or by...
Only pharmaceutical entrepreneurs meeting the AMG and authorisation conditions may participate.
Submission deadline in 3 days
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Applicant must be a pharmaceutical entrepreneur within the meaning of Section 4(18) AMG for the relevant medicinal product.
- Applicant must have its seat in the scope of the AMG, another EU Member State, or another EEA state.
- Applicant must hold a valid marketing authorisation for the relevant medicinal product or otherwise be entitled to place it on the market in its own name.
Critères d'attribution
Lot 1
Acheteur
Localisation
Hamburg, DEU
Site web
Identifiant
992-80116-93
Activité
Health
Lots (1)
LOT-0001
Open House Originale rebate agreements for Dapagliflozin
Open House contract for rebate agreements under Section 130c SGB V for the active substance Dapagliflozin. Scope is nationwide in Germany. The lot information comes from structured data and the notice text. No lot value is stated. The procedure is open to eligible pharmaceutical companies during the contract period.
Localisation
Durée
Catégorie
Critères d'attribution
Date limite
Détails des critères
Participation and suitability requirements in the Open House procedure
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Open House Originale Rabattverträge 2024-07 - Dapagliflozin
Description TED originale
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c SGB V zum Wirkstoff Dapagliflozin zu schließen.
Détails de la procédure
- Date de publication
- 19 Jul 2024
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 434034-2024
Documents (1)
Appels d'offres similaires
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Score d'opportunité
Pourquoi ce score ?
Opportunité
56 / 100
Complexité
48 / 100
Facteurs de risque
Contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature or by...
Only pharmaceutical entrepreneurs meeting the AMG and authorisation conditions may participate.
Submission deadline in 3 days
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications